MARKET

SLXN

SLXN

Silexion Therapeutics Corp
NASDAQ
1.310
+0.030
+2.34%
After Hours: 1.338 +0.028 +2.14% 19:58 03/14 EDT
OPEN
1.310
PREV CLOSE
1.280
HIGH
1.360
LOW
1.270
VOLUME
441.61K
TURNOVER
--
52 WEEK HIGH
122.02
52 WEEK LOW
0.5750
MARKET CAP
5.23M
P/E (TTM)
-1.0377
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at SLXN last week (0303-0307)?
Weekly Report · 5d ago
Biotech Alert: Searches spiking for these stocks today
TipRanks · 03/07 16:06
Silexion Therapeutics Receives Buy Rating from Naz Rahman Following Promising SIL-204 Pre-Clinical Results
TipRanks · 03/06 20:26
3 Penny Stocks to Watch Now, 6/3/25
TipRanks · 03/06 11:02
Silexion Therapeutics' Preclinical Cancer Candidate Shows Tumor Reduction For Pancreatic Cancer
Benzinga · 03/05 17:05
Silexion Therapeutics Reports Positive Data for SIL204
TipRanks · 03/05 14:18
Silexion reports initial data from systemic administration of SIL204
TipRanks · 03/05 13:43
Silexion Therapeutics Reports Groundbreaking Initial Data From Systemic Administration Of SIL204 In Orthotopic Pancreatic Cancer Models Demonstrating That Subcutaneously Administered SIL204 Effectively Reduces Both Primary Tumor Growth And Metastatic Spread
Benzinga · 03/05 13:35
More
About SLXN
Silexion Therapeutics Corp is an oncology-focused biotechnology company. The Company is engaged in the development of treatments for unsatisfactorily treated solid tumor cancers, which have the mutated KRAS oncogene. The KRAS gene is an oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals to the cell nucleus. Based on its research of refractory solid tumor cancers, it is developing a platform focused on the silencing of the KRAS oncogene using ribonucleic acid (RNA)-interference therapeutics. Its lead product candidate, SIL-204B, consists of locally administered small interfering RNAs (siRNA), in an extended-release formulation, as a first-line treatment of locally advanced pancreatic cancer patients, in combination with standard-of-care chemotherapy. Its clinical-stage pipeline is focused on treatment for pancreatic cancer (PC) tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected.

Webull offers Silexion Therapeutics Corp stock information, including NASDAQ: SLXN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SLXN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SLXN stock methods without spending real money on the virtual paper trading platform.